Dedicated to improving human health by facilitating key medical breakthroughs and their applications worldwide
MANAGEMENT TEAM
An international and professional team with veteran management
Jack (Bing) Yang
Founding Partner
- Over 25 year experiences in (VC/PE) investment and M&A investment banking acquired with New Hope Industry Funds, Rothschild Investment Banking, China Leasing, etc. in Beijing, Tokyo, London, Hong Kong, and Shenzhen
- BA Economics, Peking University; Msc Finance, London Business School
Lisa (Li) Feng
Partner
- Over 20 year experiences in pharmaceutical industry with Brightech International, Theravance, Anacor Pharmaceuticals, Kosan Biosciences
- B.S., Chemistry, Peking University; M.S., Biochemistry and Molecular Biology, UNIVERSITY OF IOWA
Samuel (SY) Cheung
Partner
Over 30 years of founding startups experience and business management experience acquired while assuming senior management / board director roles with HK listed companies and HK and PRC private companies.
Xin Wan
Partner
- Over 30 years of founding startups experience in various industries such as high technology industry, chain business, bulk commodity, new energy resources, studios and animation, creative park, real estate, venture capital, etc.
- Master of Systems Engineering, Shanghai Jiao Tong University
Qinghao Fu
Managing Director
- Over 15 years of experience in healthcare and life science industries with functions ranging from neuroscience research, marketing research and investing
- B.S., Biology, Peking University; M.S., Neuroscience, Boston University, MBA, Washington University in St. Louis
Ofer Hornick (MD)
Senior Consultant Regulatory Affairs
- Over 20 year experiences in R&D, regulatory affairs (FDA, CE, etc.) and founding startups in the fields of medical devices and digital health
- MD, Sackler Faculty of Medicine, Tel-Aviv University
NEWS
Yangtze River Pharmaceutical strategic investment in Binhui bio
September 29th，2021
Yangzi River Pharmaceutical Group reached a strategic cooperation with Wuhan Binhui Biotechnology Co., Ltd., an independent R & D enterprise of oncolytic virus drugs, and announced that the two sides would strengthen cooperation in the field of biomedicine.
Caretaker Medical receives new investment from Philips and others to enhance the Caretaker wireless Vital Signs patient monitoring platform
Caretaker Medical, a leader in clinical-grade wireless patient monitoring and maker of the Caretaker® wearable patient monitor that utilizes a simple Finger Cuff to remotely measure “Beat by Beat” Continuous Blood Pressure and multiple vital signs has announced the completion of a Series B funding round from new investors Philips and Ming Capital, with participation from existing investors including IrishAngels, Felton Group LLC, and others.
Miracor Medical’s PiCSO® System Receives CE Mark
Miracor Medical SA (Miracor Medical) has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients.
Miracor Medical Granted FDA Breakthrough Device Designation for the PiCSO Impulse System on August 22nd, 2019
Miracor Medical SA (Miracor Medical) has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its PiCSO® Impulse System for treatment of STEMI patients.
In July of this year, Miracor announced the start of its European randomized study, PiCSO-AMI-I, to further evaluate the benefits of PiCSO therapy as compared with conventional PCI for the treatment of anterior STEMI patients.
Miracor Medical closes final tranche of Series-D, bringing the round to €30M on September 4th, 2018
The Series D capital will be used to further develop and commercialize the PiCSO® Impulse System. The Series-D round was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor. Participating new investors include Belgian alternative investment fund Quest for Growth, and participating existing investors include Ming Capital, SFPI and Meusinvest. The technical and clinical research programs of Miracor are also supported by a financing program of the DGO6 (Walloon Government).
Miracor Medical Raises € 25M on January 4th, 2018
Miracor Medical today announced the closing of € 25m as part of a Series D financing round. The new capital will be used to further develop and commercialize the PiCSO® Impulse System. The round was led by Ming Capital (Shenzhen, China) and co-led by a strategic investor.
视微影像完成超3亿元C轮融资，眼科器械国产替代拐点已至
动脉网独家获悉，视微影像有限公司（后文简称“视微”）目前宣布完成超3亿元人民币C轮融资。本轮融资由国寿股权与前海方舟领投，辰德资本、深创投、中金汇融、华创毅达、临港蓝湾、小明投资跟投，原机构股东继续加注，硬科技领域知名FA机构云岫资本担任独家财务顾问。
CONTACT
info@
mingcapital.cn 
1610, 6009 Yitian Road Shenzhen, China (518038)
+86 (755) 2399 8758
